CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin combines two growth-hormone-axis research peptides in a single 5mg/5mg vial. CJC-1295 here is the No-DAC form (modified GRF 1-29), a short-acting GHRH analog, paired with Ipamorelin, a selective GHS-R1a agonist. The two mechanisms — a GHRH analog and a selective secretagogue — are frequently studied together, and the pre-combined vial keeps them in a consistent research ratio.

In research models this pairing is examined for pulsatile GH secretion that follows a physiological-pattern rather than a sustained one — the No-DAC form of CJC-1295 is specifically studied because it avoids the DAC-mediated accumulation associated with the longer-acting variant. Ipamorelin contributes a clean secretagogue mechanism studied without the cortisol or prolactin interference seen with some alternatives. All work with this material is intended strictly for in-vitro laboratory research.

This blend is supplied as a single fixed 5mg/5mg configuration rather than in multiple sizes, because the equal-ratio pairing is the point of the formula — a consistent proportion of GHRH-analog to secretagogue across batches. The vial is lyophilized and third-party lab tested at ≥98% purity by HPLC, with a Certificate of Analysis available on request by email. Store the vial cool, dry, and away from direct light; refrigeration is recommended for longer-term storage, and repeated temperature swings should be avoided.